LANSING, Mich., Oct. 13, 2008 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCBB:KBLB) is pleased to announce that genetic engineer Dr. Bong-Hee Sohn has joined the research and development team to develop new high performance polymers using spider silk gene sequences.
Dr. Sohn received her Ph.D. from Kyung-Hee Univ. in South Korea. Her extensive research background includes work in research laboratories in Japan and South Korea. One of her areas of specialty in genetic engineering is the development of novel methods for transgenic silkworm production.
"Dr. Sohn has already made a significant impact on the pace and direction of our development program. This is a very exciting time for the Company and for the research laboratory," said the CEO Kim K. Thompson. "The University of Notre Dame hired Dr. Sohn to work on specific applications of genetic engineering in silkworm for polymer development and protein expression platform technologies, which are the Company's major areas of focus. We would like to express our congratulations to the research team for their foresight in initiating this addition and expansion. The Company is now fully on target for significantly accelerating the pace of its R & D."
Dr. Sohn is the third major addition to the research and development team over the last six months. The Company anticipates that it will be able to announce the hiring of additional scientists and researchers within the University research laboratory in the coming weeks as the Company continues to accelerate the pace of its work.
Kraig is working to develop and commercialize high performance polymers using spider silk gene sequences. The company hopes to tap into the $92 billion market for high performance and technical fibers. In 2007 Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame. Since that time the Company has been a proud sponsor of scientific research within the University.
For more information on Kraig Biocraft Laboratories, and to hear an audio interview with Kraig's CEO, please visit the Company's web site: www.KraigLabs.com.
The Kraig Biocraft Laboratories, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4817
Statements in this press release about the company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "hopes," "develops", "researching," "research," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.